1 The EIC Accelerator Project

The EIC Accelerator program is a flagship initiative of the European Innovation Council (EIC) aimed at supporting small and medium-sized enterprises (SMEs) and startups in Europe that are developing innovative technologies and solutions, particularly in the DeepTech sector. The program is designed to address the funding gap that often exists for high-risk, high-potential projects, providing financial support to help these companies scale and bring their innovations to market.

Funding Structure

The EIC Accelerator offers a dual funding mechanism comprising grants and equity investments. The grant component can provide up to €2.5 million, aimed at covering the costs associated with project development, including research, prototyping, testing, and other essential activities necessary to advance a product or service towards commercialization.

In addition to the grant, the equity funding option allows eligible companies to secure funding of up to €15 million until 2024. This amount is intended to help businesses scale significantly, covering costs such as market entry, international expansion, and operational scaling. Starting in 2025, the maximum equity funding will be reduced to €10 million, reflecting a shift in funding strategy while still providing substantial financial support.

Purpose and Ecosystem Role

The EIC Accelerator serves a crucial role in the European startup ecosystem, particularly within the DeepTech sector, which encompasses advanced technologies such as artificial intelligence, biotechnology, and advanced materials. By providing financial support alongside tailored mentoring and coaching services, the EIC Accelerator helps companies not only to innovate but also to effectively navigate the challenges of market entry and competition.

This program aims to bridge the gap between public funding and private investment, encouraging private sector participation by reducing the perceived risks associated with innovative projects. By validating and supporting promising startups, the EIC Accelerator enhances their attractiveness to private investors, thereby facilitating a smoother path to scaling and commercialization.

EIC Accelerator Winner: S.I.T. - Sordina IORT Technologies S.p.A.

One notable winner of the EIC Accelerator is S.I.T. - Sordina IORT Technologies S.p.A., an Italian company recognized for its groundbreaking project, LIAC FLASH. The project, which focuses on life-changing Intraoperative Electron Radiation Therapy (IOeRT) technologies for oncology care, was submitted as a Step 2 proposal on June 15, 2022, and subsequently won in the Step 3 interview phase.

Project Overview: LIAC FLASH

LIAC FLASH represents a significant advancement in cancer treatment methodologies. The project centers on the development of a novel IOeRT technology that aims to enhance the precision and effectiveness of radiation therapy during surgical procedures. This approach allows for targeted radiation delivery to tumor sites while sparing surrounding healthy tissues, which is critical in minimizing side effects and improving patient outcomes.

Technology Basics and Background

The underlying technology of LIAC FLASH is based on the principles of intraoperative radiation therapy, a technique where radiation is administered directly to the tumor bed during surgery. This method contrasts with conventional radiation therapy, which typically occurs post-surgery over several weeks. By delivering radiation during surgery, LIAC FLASH aims to:

The LIAC FLASH project aligns with ongoing trends in oncology that favor personalized and precise treatment options, representing a shift towards more effective and patient-centric cancer care. The funding from the EIC Accelerator is expected to propel S.I.T. - Sordina IORT Technologies S.p.A. into the next phase of development, facilitating further research, clinical trials, and eventual market entry for this innovative technology.

The EIC Accelerator’s support is instrumental in enabling companies like S.I.T. to transform their ambitious ideas into real-world solutions, ultimately contributing to advancements in healthcare and improving the quality of life for patients facing cancer treatment.

2 The Funding Rounds

# S.I.T. Sordina IORT Technologies: EIC Accelerator Success Story

S.I.T. Sordina IORT Technologies S.p.A. is a leading Italian medical technology company that specializes in designing, manufacturing, and distributing miniaturized mobile electron linear accelerators for Intra Operative electron Radiation Therapy (IOeRT) and FLASH Radiation Therapy research systems. Based in Vicenza, Italy, the company has established itself as one of the few global manufacturers in this specialized medical technology field.

EIC Accelerator Funding

S.I.T. Sordina IORT Technologies received the prestigious European Innovation Council (EIC) Accelerator funding in June 2022. The company submitted its Step 2 proposal on June 15, 2022, and subsequently succeeded in the Step 3 interview phase, joining other notable EIC fund beneficiaries from that period such as Antabio, Arthex Biotech, FineHeart, and Paptic.

The EIC Accelerator program is designed to support innovative startups and SMEs with breakthrough technologies that require significant funding to scale up. While the exact funding amount received by S.I.T. Sordina IORT Technologies is not explicitly stated in the available information, EIC Accelerator typically provides a combination of grant funding and equity investments.

Company Financial Profile

As of 2025, S.I.T. Sordina IORT Technologies reports an annual revenue of approximately $25 million. The company employs 23 people and operates from its headquarters in Vicenza, Veneto, Italy. Founded in 2013, S.I.T. has established itself as a specialized player in the medical technology sector, particularly in radiation therapy equipment for cancer treatment.

Company Milestones and Growth

The company's growth trajectory includes several significant milestones:

• Installing the first NOVAC 7 produced by NRT at S. Filippo Neri Hospital in Rome
• Installing the first LIAC produced by Sordina at the European Institute of Oncology in Milan
• Acquiring NRT through an M&A operation
• Establishing SIT as a new business entity
• Obtaining patents for the measurement of IOeRT beam energy
• Receiving CE certification for LIAC HWL
• Obtaining patent for HWL (PCT/IT2019/050003)
• Securing CE certification for IOeRT ECHO TPS
• Developing FLASH technique (patent pending)

Market Position

S.I.T. Sordina IORT Technologies competes in the industrial linear accelerator market alongside major players such as Mitsubishi Heavy Industries, Siemens Healthineers, Elekta AB, Accuray Incorporated, and others. The company is positioned as the only Italian manufacturer, and one of the few worldwide, capable of designing and producing miniaturized mobile electron linear accelerators for cancer treatment.

The global industrial linear accelerator market is projected to reach $4.09 billion by 2029, growing at a CAGR of 6.7%, indicating a positive outlook for companies like S.I.T. in this specialized sector.

Innovation Focus

The company has demonstrated a strong commitment to innovation, particularly with the development of the LIAC HWL FLASH, described as "the first IOeRT FLASH device designed to bring FLASH Radiation Therapy to clinical applications". This system can operate in three different modalities: conventional IOeRT, FLASH RT clinical mode, and FLASH RT research mode.

S.I.T. is also involved in collaborative research projects, such as the "W-SHIELD" project, which focuses on designing thin and flexible cosmic radiation shieldings for use in outer space. This project is co-financed by the European Union.

Current Status and Future Outlook

As a privately owned company, S.I.T. Sordina IORT Technologies continues to focus on innovation in cancer treatment technologies. The company's participation in the EIC Accelerator program suggests a strategic growth phase aimed at scaling its technologies and expanding its market reach.

While information about potential exit events such as IPOs or acquisitions is not available in the provided sources, the company's specialized technology and position in a growing market segment make it a potentially valuable player in the medical technology industry.

Sources: - S.I.T. Sordina IORT Technologies company information, funding

• S.I.T. Sordina IORT Technologies S.p.A. Information - RocketReach
• Soiort – S.I.T. Sordina IORT Technologies S.p.A.
• Industrial Linear Accelerator Market Report 2025 - Share & Outlook
• S.I.T. Sordina IORT Technologies company information, funding

3 The Press Releases

S.I.T. - Sordina IORT Technologies S.p.A.

S.I.T. - Sordina IORT Technologies S.p.A., an Italian company, specializes in designing, manufacturing, and distributing miniaturized mobile electron linear accelerators for Intra Operative electron Radiation Therapy (IOeRT) and FLASH Radiation Therapy research systems. Following its success in the EIC Accelerator funding in June 2022, SIT has continued to innovate in the field of radiation therapy.

Technological Advancements

• FLASH Radiation Therapy: SIT developed the LIAC HWL FLASH, a pioneering device for FLASH Radiation Therapy, designed to operate in clinical and research modes. This technology offers excellent radiation protection, allowing its use in any operating room without additional shielding.
• IOeRT Systems: The company has also been involved in the development of IOeRT systems, providing a crucial advancement in treating cancer during surgical procedures.

Partnerships and Projects

W-SHIELD Project: SIT is part of the W-SHIELD project, focusing on designing thin and flexible cosmic radiation shields using hybrid tungsten polymeric dust. This project combines advanced manufacturing techniques like electrospinning and 3D printing. The final products have potential applications in both clinical settings and outer space.

Certifications and Patents

SIT has obtained CE certification for its LIAC HWL device and is working on patents related to IOeRT beam energy measurement and FLASH technique development.

Press Releases and Updates

While specific press releases from SIT's website are not detailed, the company's advancements in radiation therapy technologies are significant. SIT's involvement in innovative projects like W-SHIELD and its contributions to FLASH and IOeRT technologies highlight its commitment to advancing medical radiation technology.

Sources

• Soiort – S.I.T. Sordina IORT Technologies S.p.A.
• IORT – Soiort
• "Flash" radiotherapy: another step towards clinical applications for Institut Curie and SIT
• Intraoperative Radiation Therapy Market Report (2022 to 2030)
• Radiotherapy/Radiation Oncology Devices Market Insights

4 The Technology Advancements

S.I.T. Sordina IORT Technologies: Post-EIC Accelerator Advancements S.I.T. Sordina IORT Technologies S.p.A., an Italian innovator in intraoperative electron radiation therapy (IOeRT), has solidified its position as a global leader in mobile electron linear accelerators for precision cancer treatment. Since mid-2022, the company has expanded its technological capabilities and market presence through several key initiatives:

Technological Advancements

• LIAC HWL FLASH System: The company’s flagship device now supports three operational modes—CONV IOeRT for conventional treatments, FLASH RT clinical mode for ultra-high-dose-rate delivery, and a dedicated research mode for experimental applications. This system operates without requiring additional room shielding, making it adaptable to standard operating theaters.
• Radiation Protection Innovations: Recent U.S. patent approvals highlight enhancements in minimizing stray radiation from IORT linear accelerators (LINACs), improving safety during procedures. These advancements reduce reliance on mobile barriers and streamline workflow efficiency.

Market Deployment & Clinical Integration

While explicit post-2022 customer installations are not detailed in public reports, the company’s participation in the EU-funded W-SHIELD project underscores its focus on radioprotection advancements applicable to both clinical oncology and space exploration. The LIAC HWL FLASH’s design aligns with growing demand for portable systems that integrate with robotic surgery and intraoperative imaging technologies—a trend emphasized in industry forecasts.

Intellectual Property & Research Outputs

• Patents: Beyond the U.S. patent granted for radiation protection technology, SIT holds multiple patents related to beam energy measurement (PCT/IT2019/050003) and dose-planning software (CE-certified IOeRT ECHO TPS).
• Clinical Evidence: While no new peer-reviewed studies are explicitly cited post-June 2022, historical literature positions IOeRT as critical for reducing local tumor recurrence through precision dosing—a principle central to SIT’s devices.

Strategic Collaborations & Future Directions

SIT’s involvement in cross-sector projects like W-SHIELD reflects a strategy to diversify applications of its radiation-shielding expertise while optimizing medical device manufacturing processes. Industry analyses project significant growth for IORT technologies like those developed by SIT due to their alignment with value-based care models emphasizing reduced hospitalization times and improved therapeutic precision.

---

Sources

• Soiort – Company Overview
• US Patent Grant Announcement
• W-SHIELD Project Collaboration (via internal blog mention)

5 The Partnerships and Customers

S.I.T. - Sordina IORT Technologies S.p.A.

Since receiving the EIC Accelerator funding in June 2022, S.I.T. - Sordina IORT Technologies S.p.A., an Italian company specializing in intraoperative radiation therapy (IORT) and FLASH radiation therapy systems, has continued to innovate and expand its partnerships.

Partnerships and Customers

S.I.T. is known for its involvement in the W-SHIELD project, aiming to develop thin and flexible cosmic radiation shieldings using advanced manufacturing techniques like electrospinning and 3D printing. This collaboration highlights the company's commitment to innovative technologies beyond medical applications. However, specific new customers or partners announced since the EIC funding are not detailed in available information.

Nature of Relationships

The partnerships, such as that with the W-SHIELD project, reflect S.I.T.'s focus on cutting-edge technology and its ability to contribute to diverse applications, from medical devices to space-related innovations. These relationships position S.I.T. as a versatile player in radiation therapy and beyond.

Market Positioning

By engaging in projects like W-SHIELD, S.I.T. enhances its reputation for technological advancement and innovation. This can attract new partnerships and customers interested in both medical and space-related technologies. The company's expertise in designing and manufacturing miniaturized mobile electron linear accelerators for IORT and FLASH RT further solidifies its market presence in radiation oncology.

Technology Advancements and Scaling

Partnerships and projects like W-SHIELD can help S.I.T. in technology advancements by fostering cross-industry collaboration and knowledge sharing. For instance, the development of radiation shielding technologies could lead to improvements in medical device safety and efficiency. Scaling is likely to occur through increased recognition and potential adoption of S.I.T.'s innovative solutions in both medical and non-medical sectors.

Products and Innovations

S.I.T. has developed notable products such as the ElectronFlash for FLASH RT and the LIAC HWL for IORT, which are designed to be used in clinical and research settings without additional shielding. These innovations underscore the company's commitment to advancing radiation therapy technologies.

Sources: - S.I.T. – Sordina IORT Technologies S.p.A.

• The Best Partner for Radiation Therapy
• Electron Beam Linear Accelerators Market

6 The Hiring and Company Growth

S.I.T. - Sordina IORT Technologies S.p.A.: Post EIC Accelerator Funding

S.I.T. - Sordina IORT Technologies S.p.A., an Italian company specializing in the design, manufacture, and distribution of miniaturized mobile electron linear accelerators for intraoperative electron radiation therapy (IOeRT) and FLASH radiation therapy, secured EIC Accelerator funding on June 15, 2022.

Current Headcount and Team Size

There is no specific information available regarding the current headcount or team size of S.I.T. - Sordina IORT Technologies S.p.A. However, the company's specialized role in producing advanced medical technology suggests a focus on expertise over large-scale employment.

Hiring and Team Growth

Details about current hiring processes or recent team growth are not publicly disclosed. However, the EIC Accelerator funding likely supports strategic hiring and expansion in specialized areas such as engineering, research, and development to enhance its technological offerings.

Recent Key Positions and Impact

While specific key positions recently hired are not detailed, the company's focus on innovative technologies like the LIAC HWL FLASH device implies a need for skilled engineers and researchers. These new team members would be crucial for advancing the company's FLASH radiation therapy capabilities and expanding its market presence.

Future Outlook and Scaling

The EIC funding will significantly aid S.I.T. - Sordina IORT Technologies S.p.A. in scaling its operations by enhancing its product line, particularly in FLASH radiation therapy, and facilitating the integration of its technologies into clinical settings. This expansion could lead to increased partnerships and market penetration, positioning the company as a leader in IOeRT and FLASH technology.

Management and Founding Team Changes

There is no available information regarding major changes in management or the founding team since receiving the EIC funding.

Conclusion

S.I.T. - Sordina IORT Technologies S.p.A. is poised for growth and innovation with its recent EIC Accelerator funding. The company's focus on advanced radiation therapy technologies will likely drive strategic hiring and expansion in specialized technical roles, contributing to its future success and market influence.

Sources

• S.I.T. Sordina IORT Technologies S.p.A.
• Electron Beam Linear Accelerator Insights
• S.I.T. - Sordina IORT Technologies S.p.A. Overview
• S.I.T. - Sordina IORT Technologies S.p.A.

7 The Media Features and Publications

S.I.T. - Sordina IORT Technologies S.p.A.: An Overview Since EIC Accelerator Funding

Company Background and Recent Developments

S.I.T. - Sordina IORT Technologies S.p.A., an Italian company, received the EIC Accelerator funding on June 15, 2022. This funding marked a significant milestone for the company, which specializes in intraoperative radiation therapy (IORT) systems. IORT is a pioneering technique that delivers concentrated radiation doses directly to tumor sites during surgery, offering precision and reduced harm to surrounding healthy tissues.

Since receiving the funding, S.I.T. - Sordina IORT Technologies has been active in advancing its technological portfolio. For instance, Dr. Fabio di Martino and his team have developed a new model for dosimetric characterization of UHDR devices, further enhancing their technological capabilities.

Media Features and Publications

Several publications have highlighted S.I.T. - Sordina IORT Technologies for its contributions to the field of IORT:

• Good Samaritan Medical Center News: Featured the company's method of delivering high-dose radiation directly to the tumor bed during surgery for breast cancer patients.
• RAD Magazine: Covered the partnership between Sordina IORT Technologies and Vertec to sell and support IORT systems in the UK, emphasizing the effectiveness of IORT in breast cancer treatment.

Content from Publications

Publications have emphasized the company's role in providing innovative IORT solutions. The technology allows for precise targeting of cancer cells, reducing the risk of recurrence and minimizing damage to healthy tissues.

Podcasts or Interviews

There is no specific information available about podcasts or interviews featuring the team from S.I.T. - Sordina IORT Technologies.

Conference and Fair Visits, Presentations or Participations

The company has been involved in industry events, such as the FRPT 2022 conference, where they participated in industry-supported sessions. Additionally, Vertec product specialists visited Sordina's manufacturing site in Rome for training on their compact IORT systems.

Involvement in Events

S.I.T. - Sordina IORT Technologies has engaged in various industry events, highlighting their commitment to advancing IORT technology and collaborating with other stakeholders in the medical technology sector.

Sources

• News – Soiort
• News – Pagina 4 – Soiort
• Good Samaritan Medical Center Introduces New Method of Delivering Radiation Therapy to Breast Cancer Patients
• Product specialists learn about compact IORT systems
• Intraoperative Radiation Therapy (IORT) Market is Anticipating 6-8% Growth
• Intra-Operative Electron Radiation Therapy (IOERT) Anticipated
• The future of radiotherapy - YouTube
• Industry Supported Sessions Timetable - FRPT 2022
• Trade-marks Journal Vol. 62 No. 3191
• Intraoperative Radiation Therapy Market is Prospering at USD 413.90 Million by 2028